Replies to post #181487 on Biotech Values

[biomaven0]

Here's a post on the subject I made a while back on SI:

>>Stanford group develops a potential blood test for ALK/ROS/EGFR:

http://www.nature.com/nm/journal/vaop/ncurrent/abs/nm.3519.html

What they are doing is pretty complex, but basically they use deep sequencing of circulating tumor DNA looking for known mutations using hybrid targeting. Potentially could be used as a screening test or to follow mutations under treatment.


Probably a few years out yet, but very important in the long run. Getting tumor material for a lung biopsy is sometimes quite hard and can have significant morbidity.